biopharmaceutical industry Syndicate content

May 28, 2019

Partnership accelerates access to inebilizumab in China and supports the mission of both companies to bring transformative therapies to more patients around the world

Viela Bio is eligible to receive an upfront collaboration fee and milestone payments of more than $220 million plus royalties on product sales...